Two Novel Insulin Receptor Gene Mutations in a Patient with Rabson-Mendenhall Syndrome: The First Korean Case Confirmed by Biochemical, and Molecular Evidence.
10.3346/jkms.2012.27.5.565
- Author:
Doosoo KIM
1
;
Sung Yoon CHO
;
Sung Hee YEAU
;
Sung Won PARK
;
Young Bae SOHN
;
Min Jung KWON
;
Ji Yeon KIM
;
Chang Seok KI
;
Dong Kyu JIN
Author Information
1. Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. jindk@skku.edu
- Publication Type:Case Reports
- Keywords:
Rabson-Mendenhall Syndrome;
Insulin Resistance;
Receptor, Insulin;
INSR
- MeSH:
Asian Continental Ancestry Group/*genetics;
Base Sequence;
Blood Glucose/analysis;
C-Peptide/blood;
Codon, Nonsense;
Donohue Syndrome/drug therapy/*genetics;
Heterozygote;
Humans;
Hypoglycemic Agents/therapeutic use;
Infant;
Insulin/blood;
Male;
Mutation, Missense;
Receptor, Insulin/*genetics;
Republic of Korea;
Sequence Analysis, DNA
- From:Journal of Korean Medical Science
2012;27(5):565-568
- CountryRepublic of Korea
- Language:English
-
Abstract:
Rabson-Mendenhall syndrome (RMS) is a rare syndrome manifested by extreme insulin resistance with hyperinsulinemia, acanthosis nigricans, tooth dysplasia and growth retardation. Our patient was first noted at the age of 8 months due to pigmentations on skin-folded areas. Initial laboratory tests showed normal fasting glucose (69 mg/dL). Fasting insulin level was severely elevated, up to 554.6 microIU/mL, and c-peptide level was increased, up to 13.81 ng/mL. However, hemoglobin A1c was within normal range (4.8%). He is now 11 yr old. His growth development followed the 5-10th percentile and oral hypoglycemic agents are being administered. The last laboratory results showed insulin 364.1 microIU/mL, C-peptide 4.30 ng/mL, and hemoglobin A1c 7.6%. The boy was a compound heterozygote for the c.90C > A and c.712G > A mutations of the insulin receptor gene, INSR, which are nonsense and missense mutations. In summary, we report the first Korean case of RMS, which was confirmed by two novel mutations of the INSR.
